Clinical trial · Observational
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
NCT04324151CI-TRIAL-00080759recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS
- timeFrame
- may 2020- may 2021 (1 year)
- description
- Progression free survival
Secondary outcomes (2)
- measure
- OS
- timeFrame
- may 2020- may 2021 (1 year)
- description
- Overall survival
- measure
- ORR
- timeFrame
- may 2020- may 2021 (1 year)
- description
- To measure the patients's overall response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Potentially Resectable NSCLC * Treatment Plan is Crizotinb or Standard Chemotherapy Exclusion Criteria: * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
References
Publications (0)
Data not yet available
No reference posted for this study.